TGF-beta receptor 1 inhibitor GFH018

{
  "id": "MLC-T-ONC-017100",
  "term": "TGF-beta receptor 1 inhibitor GFH018",
  "field": "Oncology and biomedicine",
  "definition": "An orally bioavailable inhibitor of transforming growth factor-beta receptor 1 (TGFbR1), with potential antineoplastic activity. Upon oral administration, TGFbR1 inhibitor GFH018 specifically targets and binds to TGFbR1, which prevents TGFbR1-mediated signal transduction. This abrogates TGFbR1-mediated immunosuppression, enhances anti-tumor immunity in the tumor microenvironment (TME) and promotes a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells leading to tumor cell death. This may lead to a reduction in TGFbR1-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, and angiogenesis. It plays a key role in immunosuppression in the TME.",
  "synonyms": [
    "TGFbR1 inhibitor GFH018",
    "transforming growth factor-beta receptor 1 inhibitor GFH018"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/tgf-beta-receptor-1-inhibitor-gfh018/"
}